GRAIL, Inc. Common Stock earnings per share and revenue
On Nov 12, 2025, GRAL reported earnings of -2.46 USD per share (EPS) for Q3 25, beating the estimate of -3.58 USD, resulting in a 31.44% surprise. Revenue reached 36.19 million, compared to an expected 36.11 million, with a 0.24% difference. The market reacted with a -1.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -3.18 USD, with revenue projected to reach 44.37 million USD, implying an increase of 29.27% EPS, and increase of 22.59% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were GRAIL, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, GRAIL, Inc. Common Stock reported EPS of -$2.46, beating estimates by 31.44%, and revenue of $36.19M, 0.24% above expectations.
How did the market react to GRAIL, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.85%, changed from $84.77 before the earnings release to $83.20 the day after.
When is GRAIL, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for GRAIL, Inc. Common Stock's next earnings report?
Based on 6
analysts, GRAIL, Inc. Common Stock is expected to report EPS of -$3.18 and revenue of $44.37M for Q4 2025.